Publications & Presentations

Presentations and Posters

Early Change in Bilirubin Level (ECBL) as a Surrogate for Outcome in ELAD Clinical Study of Severe Alcoholic Hepatitis (sAH) (Hassanein, et al, APASL 2017)

Phosphatidylethanol (PEth) in Blood as Marker of Alcohol Relapse (AR) in Subjects with Severe Alcoholic Hepatitis (sAH) in the ELAD Phase 3 Clinical Trial (Mac Nicholas, et al, AASLD 2016)

Hypothesis Generation in Clinical Development: The Evolution of the VTL-308 Trial Parameters (Ashley, et al, ISAD 2016)

VTL-C3A Cell-Secreted Factors Reduce In Vitro Hepatocellular Injury via Multiple Mechanisms Poster (Lapetoda, et al, ISAD 2016)

VTL-C3A Cell-Secreted Factors Reduce In Vitro Hepatocellular Injury via Multiple Mechanisms Presentation (Lapetoda, et al, ISAD 2016)

Hepatic Inflammation and Cellular Therapy Poster (Landeen, et al, ISAD 2016)

Hepatic Inflammation and Cellular Therapy Presentation (Landeen, et al, ISAD 2016)

Early Intervention with Extracorporeal C3A Cellular Therapy in Patients with Alcoholic Hepatitis with MELD less than 28 May Result in Clinical Benefit and Less Need for Later Transplantation (Lake, ILTS 2016)

ELAD VTL C3A Cells May Impact Liver Regeneration through Secreted Factors (Bedard, et al, AASLD, November 17, 2015)

The Effect of Extracorporeal C3A Cellular Therapy in Severe Alcoholic Hepatitis-The ELAD Trial (AASLD Late-Breaking Abstract LB1 presented on November 16, 2015 by Dr. David J. Reich, Professor and Vice Chairman of the Department of Surgery at Drexel University College of Medicine)

Additional VTI-208 Data Analysis

Appropriate Patient Selection as a Key to Increase the Benefit/Risk Ratio for ELAD (Subramanian, Rostock, August 29, 2015)

Acute Alcoholic Hepatitis and Liver Support (Thompson, Rostock, August 29, 2015)

Expression of Acute-Phase Proteins by ELAD® C3A Cells (Landeen, et al, ILTS, July 9, 2015)

A Randomized, Open-label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD, a Human Cell-Based Bio-Artificial Liver Support System (ELAD), in Subjects with Alcohol-Induced Liver Decompensation (AILD) (Ashley, et al, ILC, April 25, 2015)

Expression of Liver-Specific Cytochrome P450 Isoenzymes and Oxygenases in C3A Cells Prior to and After Treatment with the ELAD Liver Support System (Landeen, et al, ILC, April 24, 2015)

Protein Content Assessment During Treatment with the ELAD® Bioartificial Liver Support System (Teperman, et al, WTC, July 27, 2014)

Bilirubin Improvement Correlates with 90-Day Survival with the Use of the ELAD® System in a Randomized, Controlled Study of Subjects with Acute Alcoholic Hepatitis (AAH) or Acute Decompensation of Cirrhosis (Non-AAH)
(Teperman, ATC, May 19, 2013)

Efficacy and Safety of Human Cell-based Biological Liver Support System (ELAD®) in Subjects with Acute Alcoholic Hepatitis (AAH) or Acute Decompensation of Cirrhosis (Non-AAH)
(Teperman, ILTS, May 17, 2012)

3-year follow up of acute-on-chronic liver failure (ACLF) subjects in a randomized, controlled, multicenter trial of the ELAD® Bioartificial Liver Support System in 49 Chinese subjects reveals significant transplant-free survival (TFS) benefit
(Duan, et al, AASLD, October 29 – November 2, 2010)

Safety and Efficacy of the Extacorporeal Liver Assist Device (ELAD®) in patients with Acute on Chronic Liver Failure
(Hillebrand, et al, EASL, April 17, 2010)

ELAD® Cellular and System Performance Improvements
(Brotherton, et al, AASLD, November 5, 2007)

Publications

Interim Results of Randomized Controlled Trial of ELAD™ in Acute on Chronic Liver Disease
(AASLD, 2007, p 274 A)

Initial Experience with the Modified Extracorporeal Liver-Assist Device for Patients with Fulminant Hepatic Failure: System Modifications and Clinical Impact
(Millis et al, Transplantation, December 27, 2002)